Examples of using Ipilimumab in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Ipilimumab steady-state was reached by the third dose.
Pembrolizumab 2 mg/kg every3 weeks in patients naïve to treatment with ipilimumab n=51.
Patients given only ipilimumab lived for only 2.9 months without their disease getting worse.
The dose and frequency to be given depends on whether it is used alone or in combination with ipilimumab.
When OPDIVO is given in combination with ipilimumab, you will first be given OPDIVO followed by ipilimumab.
People also translate
For Grade 2 transaminase or total bilirubin elevation,nivolumab or nivolumab in combination with ipilimumab should be withheld.
When administered in combination with ipilimumab, OPDIVO should be given first followed by ipilimumab on the same day.
Fatal Guillain-Barré syndrome has been reported in<1% of patients who received ipilimumab 3 mg/kg in combination with gp100.
In the ipilimumab 3 mg/kg monotherapy group, rash and pruritus of any severity were each reported in 26% of patients.
The use of systemic corticosteroids after starting ipilimumab treatment does not appear to impair the efficacy of ipilimumab.
Ipilimumab is a T-cell potentiator that enables the immune response(see section 5.1) and may interfere with immunosuppressive therapy, resulting in an exacerbation of the underlying disease or increased risk of graft rejection.
When nivolumab is administered in combination with ipilimumab, refer to the Summary of Product Characteristics for ipilimumab prior to initiation of treatment.
Fatalities due to gastrointestinal perforation have been reported in<1% of patients who received ipilimumab 3 mg/kg in combination with gp100.
OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced(unresectable or metastatic) melanoma in adults.
Fatal toxic epidermal necrolysis has been reported in<1% of patients who received ipilimumab in combination with gp100 see section 5.1.
In patients with melanoma who received ipilimumab, the mean peripheral blood absolute lymphocyte counts(ALC) increased throughout the induction dosing period.
Based on the severity of the adverse reaction,nivolumab or nivolumab in combination with ipilimumab should be withheld and corticosteroids administered.
The OS HRs for pooled pembrolizumab vs. ipilimumab were 0.61(95% CI: 0.46, 0.82) for BRAF wild type, 0.69(95% CI: 0.33, 1.45) for BRAF mutant without prior BRAF.
However, systemic corticosteroids or other immunosuppressants can be used after starting ipilimumab to treat immune-related adverse reactions.
Key secondary endpoints were OS in the ipilimumab+ gp100 group vs. the ipilimumab monotherapy group and in the ipilimumab monotherapy group vs. the gp100 group.
The safety profile was considered favourable compared with other treatment, including ipilimumab and chemotherapy, and side effects appear manageable.
Long term survival benefit of treatment with ipilimumab(at 3mg/kg) is demonstrated through a pooled analysis of OS data from clinical trials in patients with previously treated and treatment naive advanced melanoma N 965.
Based on the severity of the adverse reaction,nivolumab or nivolumab in combination with ipilimumab should be withheld and corticosteroids administered.
Pregnant monkeys received ipilimumab every 3 weeks from the onset of organogenesis in the first trimester through delivery, at exposure(AUC) levels either similar to or higher than those associated with the clinical dose of 3 mg/kg of ipilimumab.
The hazard ratio(HR) for comparison of OS between ipilimumab monotherapy and gp100 was 0.66 95% CI: 0.51, 0.87; p 0.0026.
A phase I study with lefitolimod(MGN1703)incombination with the commercially available immunotherapy Yervoy(R)(ipilimumab) is planned in patients with advanced solid tumours.
For symptomatic diabetes, nivolumab or nivolumab in combination with ipilimumab should be withheld, and insulin replacement should be initiated as needed.
For symptomatic hypothyroidism, nivolumab or nivolumab in combination with ipilimumab should be withheld, and thyroid hormone replacement should be initiated as needed.
For symptomatic Grade 2 or 3 hypophysitis,nivolumab or nivolumab in combination with ipilimumab should be withheld, and hormone replacement should be initiated as needed.